|
gptkbp:instance_of
|
gptkb:virus
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Herpesviridae
gptkb:herpesviridae_family
|
|
gptkbp:caps
|
icosahedral
|
|
gptkbp:caused_by
|
gptkb:roseola
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
gptkb:psychologist
febrile seizures
|
|
gptkbp:current_use
|
gptkb:healthcare_organization
gptkb:HIV/_AIDS
organ transplant complications
|
|
gptkbp:family
|
gptkb:Herpesviridae
|
|
gptkbp:first_flight
|
enveloped virus
|
|
gptkbp:first_introduced
|
from a patient with roseola
|
|
gptkbp:genus
|
gptkb:Roseolovirus
|
|
gptkbp:healthcare
|
impact on immunocompromised patients
need for awareness in healthcare
potential for outbreaks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
HHV-6
|
|
gptkbp:is_compared_to
|
over 90% in adults
|
|
gptkbp:is_popular_in
|
common in children
|
|
gptkbp:is_vulnerable_to
|
none available
|
|
gptkbp:occurs_in
|
high in infants
|
|
gptkbp:origin
|
T lymphocytes
|
|
gptkbp:performance
|
establishes latency in T cells
|
|
gptkbp:publishes
|
gptkb:physicist
|
|
gptkbp:research_focus
|
immune response
vaccine development
viral pathogenesis
|
|
gptkbp:restoration
|
can reactivate in immunocompromised individuals
|
|
gptkbp:seed_dispersal
|
approximately 150 kb
|
|
gptkbp:social_responsibility
|
gptkb:psychologist
gptkb:computer
autoimmune diseases
serology
PCR test
worldwide distribution
viral culture
|
|
gptkbp:symptoms
|
fever
rash
1 to 2 weeks
|
|
gptkbp:transmission
|
saliva
|
|
gptkbp:treatment
|
supportive care
corticosteroids
antiviral medications
intravenous immunoglobulin
clinical trials for therapies
investigating antiviral efficacy
studying immune modulation
|
|
gptkbp:type_of
|
gptkb:HHV-6_A
gptkb:HHV-6_B
|
|
gptkbp:year_created
|
gptkb:1986
|